OVERVIEW

6th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting is organized by Practical Recommendations in Immuno and Molecular Oncology (PRIMO) and will be held from Feb 10 - 12, 2021.

Accrediation:
This activity was planned by and for the healthcare team, and learners will receive 10.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician
The Medical Educator Consortium designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing
The Medical Educator Consortium designates this activity for 10.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

Pharmacist
This Application-based activity has been approved for 10.25 contact hours (1 CEU) by the Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-21-002-L01-P Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Assistant
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Educational Objectives
After completing this activity, the participant should be better able to:
• Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
• Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
• Identify patients who are appropriate candidates for targeted and immunologic therapies;
• Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
• Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

Additional details will be posted as soon as information is available.